Page 5 - Lexaria Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Right now, there is nothing that is earthmoving. That is a great way to lead off the show. I have unbelievable stuff. Okay. Lets get to our road map this morning. It does start with apples ev aboutface, reportedly abandoning its decadeslong efforts to develop an automobile, turning its focus to generative a. I. Shares have underperformed so far this year. Continued signs of a robust economy, healthy Consumer Spending certainly one reason why and goldmans ceo thinks a soft landing is uncertain. And the doj turning its focus to Health Insurance. It is launching an antitrust investigation of the ...

Stocks not doing much. Revenue forecast, certainly concerning. Well talk to jim a lot about that, and well talk a lot about snowflake. That stock is down dramatically this morning, both on guidance and the news that its ceo, Frank Slootman, will be retiring. Suboptimal. Yeah. Suboptimal. Lets start with the inflation data, sort of get that out of the way before we move on. Whats your take on this pce number . In line is cool. Thats the way i look at it. I think that there were a lot of people who thought after the cpi this one would be bad too, and when you look at the progression of the s p f...

For a growth investor, one of the top advantages of A-rated penny stocks is that they have the potential for oversized profits.

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral formatKELOWNA, BC / ACCESSWIRE / May 23, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company"

KELOWNA, BC / ACCESSWIRE / May 21, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces two important new patent